Adoptive tumor immunity mediated by lymphocytes bearing modified antigen-specific receptors

Advances in Immunology

Volumn 68, Issue , 1998, Pages 257-269

  Brocker, Thomas ^a   Karjalainen, Klaus ^a  

^a BASEL INSTITUTE FOR IMMUNOLOGY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; FC RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL MODEL; ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNOGLOBULIN VARIABLE REGION; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE SUBPOPULATION;

EID: 0031978008     PISSN: 00652776     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (43)

1. Allison, J. P., Hurwitz, A. A., and Leach, D. R. (1995). Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr. Opin. Immunol. 7, 682-686.
2. Ballas, Z. K., and Rasmussen, W. (1987). Lymphokine-activated killer (LAK) cells. III. Characterization of LAK precursors and susceptible target cells within the murine thymus. J Immunol 139, 3542-3549.
3. Ballas, Z. K., and Rasmussen, W. (1990). Lymphokine-activated killer (LAK) cells. IV. Characterization of murine LAK effector subpopulations. J. Immunol. 144, 386-395.
4. Ballas, Z. K., and Rasmussen, W. (1993). Lymphokine-activated killer cells. VII. IL-4 induces an NKl.l + CD8 alpha + beta-TCR-alpha beta B220+ lymphokine-activated killer subset. J. Immunol 150, 17-30.
5. Bentley, G. A., Boulot, C., Karjalainen, K., and Mariuzza, R. A. (1995). Crystal structure of the beta chain of a T cell antigen receptor. Science 267, 1984-1987.
6. Brocker, T., and Karjalainen, K. (1995). Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J. Exp. Med. 181, 1653-1659.
7. Brocker, T., Peter, A., Trauneeker, A., and Karjalainen, K. (1993). New simplified molecular design for functional T cell receptor. Eur. J. Immunol. 23, 1435-1439.
8. Brocker, T., Riedinger, M., and Karjalainen, K. (1996). Redirecting the complete T cell receptor/CD3 signaling machinery towards native antigen via modified T cell receptor. Eur. J. Immunol. 26, 1770-1774.
9. Cheever, M. A., Greenberg, P. D., and Fefer, A. (1984). Potential for specific cancer therapy with immune T lymphocytes. J. Biol. Response Modif. 3, 113-127.
10. Colombo, M. P., Parenza, M., and Parmiani, G. (1985). Adoptive immunotherapy of a BALB/c lymphoma by syngeneic anti-DBA/2 immune lymphoid cells: Characterization of the effector population and evidence for the role of the host's non-T cells. Cancer Immunol, Immunother. 20, 198-204.
11. De Boer, R. J., and Hogeweg, P. (1986). Interactions between macrophages and T-lymphoeytes: Tumor sneaking through intrinsic to helper T cell dynamics. J. Theor. Biol. 120, 331-351.
12. De Boer, R. J., Hogeweg, P., Dullens, H. F., De Weger, R. A., and Den Otter, W. (1985). Macrophage T lymphocyte interactions in the anti-tumor immune response: A mathematical model. J. Immunol 134, 2748-2758.
13. Demotz, S., Sette, A., Sakaguchi, K., Buchner, R., Appella, E., and Grey, H. M. (1991). Self peptide requirement for class II major histocompatibility complex allorecognition. Proc. Nad. Acad. Sci. USA 88, 8730-8734.
14. Eshhar, Z., Waks, T., Gross, G., and Schindler, D. G. (1993). Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA 90, 720-724.
15. Fass, L., and Fefer, A. (1972). Factors related to therapeutic efficacy in adoptive chemoimmu-notherapy of a Friend virus-induced lymphoma. Cancer Res. 32, 2427-2433.
16. Greenberg, P. D. (1991). Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49, 281-355.
17. Grimm, E. A., Mazumder, A., Zhang, H. Z., and Rosenberg, S. A. (1982). Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155, 1823-1841.
18. Hwu, P., Shafer, G. E., Treisman, J., Schindler, D. G., Gross, G., Cowherd, R., Rosenberg, S. A., and Eshhar, Z. (1993). Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J. Exp. Med. 178, 361-366.
19. Irving, B. A., and Weiss, A. (1991). The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 64, 891-901.
20. Lafreniere, R., and Rosenberg, S. A. (1985a). Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res. 45, 3735-3741.
21. Lafreniere, R., and Rosenberg, S. A. (1985b). Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. J. Immunol. 135, 4273-4280.
22. Letourneur, F., and Klausner, R. D. (1992). Activation of T cells by a tyrosine kinase activation domain in the cytoplasmic tail of CD3 epsilon. Science 255, 79-82.
23. Mazumder, A., and Rosenberg, S. A. (1984). Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J. Exp. Med. 159, 495-507.
24. Mazumder, A., Eberlein, T. J., Grimm, E. A., Wilson, D. J., Keenan, A. M., Aamodt, R., and Rosenberg, S. A. (1984). Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells. Cancer 53, 896-905.
25. Moritz, D., Wels, W., Mattern, F., and Groner, B. (1994). Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc. Natl. Acad. Sci. USA 91, 4318-4322.
26. Mule, J. J., Shu, S., Schwarz, S. L., and Rosenberg, S. A. (1984). Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225, 1487-1489.
27. Müller, D. L., Jenkins, M. K., and Schwartz, R. H. (1989). Clonal expansion versus functional clonal inactivation: A costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu. Rev. Immunol. 7, 445-480.
28. Pardoll, D. M. (1993). New strategies for enhancing the immunogenicity of tumors. Curr. Opin. Immunol. 5, 719-725.
29. Parmiani, G. (1990). An explanation of the variable clinical response to interleukin 2 and LAK cells. Immunol. Today 11, 113-115.
30. Refisto, N. P., Kawakami, Y., Marincola, F., Shamamian, P., Taggarse, A., Esquivel, F., and Rosenberg, S. A. (1993). Molecular mechanisms used by tumors to escape immune recognition: Immunogene therapy and the cell biology of major histocompatibility complex class I. J. Immunother. 14, 182-190.
31. Roberts, M. R., Qin, L., Zhang, D., Smith, D. H., Tran, A. C., Dull, T. J., Groopman, J. E., Capon. D. J., Byrn, R. A., and Finer, M. H. (1994). Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood 84, 2878-2889.
32. Romeo, C, and Seed, B. (1991). Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell 64, 1037-1046.
33. Rosenberg, S. A. (1988). Immunotherapy of cancer using interleukin 2: Current status and future prospects. Immunol. Today 9, 58-62.
34. Rosenberg, S. A., and Lotze, M. T. (1986). Cancer immunotherapy using interleukin-2 and interIeukin-2-activated lymphocytes. Annu. Rev. Immunol. 4, 681-709.
35. Rosenberg, S. A., Spiess, P. J., and Lafreniere, R. (1986). A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science 233, 1318-1321.
36. Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Lotze, M. T., Yang, J. C., Seipp, C. A., and Carter, C. (1988). Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319, 1676-1680.
37. Rosenberg, S. A., Yannelli, J. R., Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Weber, J. S., Parkinson, D. R., Seipp, C. A., Einhorn, J. H., and White, D. E. (1994). Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 86, 1159-1166.
38. Stancovski, I., Schindler, D. G., Waks, T., Yarden, Y., Sela, M., and Eshhar, Z. (1993). Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J. Immunol. 151, 6577-6582.
39. Stoter, G., Goey, S. H., Batchelor, D., Eggermont, A. M., Lamers, C., Gratama, J. W., and Bolhuis, R. L. (1992). Treatment of disseminated renal cell cancer with combinations of interleukin-2, lymphokine-activated killer cells, and alpha-interferon. Prog. Clin. Biol. Res. 378, 225-233.
40. Townsend, S. E., and Allison, J. P. (1993). Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected Melanoma cells. Science 259, 368.
41. Waldmann, T. A. (1991). Monoclonal antibodies in diagnosis and therapy. Science 252, 1657-1662.
42. Wegener, A. M., Letourneur, F., Hoeveler, A., Brocker, T., Luton, F., and Malissen, B. (1992). The T cell receptor/CD3 complex is composed of at least two autonomous transduction modules. Cell 68, 83-95.
43. Weijtens, M. E., Willemsen, R. A., Valerio, D., Stam, K., and Bolhuis, R. L. (1996). Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J. Immunol. 157, 836-843.